scholarly journals Effects of Extract from Solid-State FermentedCordyceps sinensison Type 2 Diabetes Mellitus

2012 ◽  
Vol 2012 ◽  
pp. 1-10 ◽  
Author(s):  
Wei-Chih Kan ◽  
Hsien-Yi Wang ◽  
Chih-Chiang Chien ◽  
Shun-Lai Li ◽  
Yu-Chun Chen ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Body Weight ◽  
Solid State ◽  
Pancreatic Beta Cells ◽  
Cell Function ◽  
Body Weight Gain ◽  
Cordyceps Sinensis ◽  
Chinese Herbs ◽  
Oral Glucose ◽  
Wide Range

Diabetes mellitus is the most common chronic disease in the world, and a wide range of drugs, including Chinese herbs, have been evaluated for the treatment of associated metabolic disorders. This study investigated the potential hypoglycemic and renoprotective effects of an extract from the solid-state fermented mycelium ofCordyceps sinensis(CS). We employed the KK/HIJ diabetic mouse model, in which the mice were provided with a high-fat diet for 8 weeks to induce hyperglycemia, followed by the administration of CS or rosiglitazone for 4 consecutive weeks. Several parameters were evaluated, including changes in body weight, plasma lipid profiles, oral glucose tolerance tests, insulin tolerance tests, and plasma insulin concentrations. Our results show that the CS extract significantly elevated HDL/LDL ratios at 4 weeks and decreased body weight gain at 8 weeks. Interestingly, CS treatment did not lead to obvious improvements in hyperglycemia or resistance to insulin, while in vitro MTT assays indicated that CS protects pancreatic beta cells against the toxic effects of STZ. CS also enhanced renal NKA activity and reduced the accumulation of mesangial matrix and collagen deposition. In conclusion, CS extract can potentially preserveβ-cell function and offer renoprotection, which may afford a promising therapy for DM.

Hypoglycemic Activity of Methanol Fraction of Tectona grandis (Linn) Bark in Experimental Rat Models

2021 ◽  
pp. 4247-4252
Author(s):  
Bishwanath Mishra ◽  
Durga M. Kar ◽  
Laxmidhar Maharana ◽  
Sujit Dash ◽  
Ganesh P. Mishra
Keyword(s):  
Diabetes Mellitus ◽  
Body Weight ◽  
Tectona Grandis ◽  
Hypoglycemic Activity ◽  
Oral Glucose ◽  
Alcoholic Extract ◽  
Traditional Use ◽  
Standard Drug ◽  
Single Dose Study ◽  
Dose Study

Diabetes mellitus (DM) is a now a major global health problem and its incidence is increasing day by day in whole world. There are various medicinal plants in India those possess antidiabetic property which are traditionally used in management of diabetes. Tectona grandis Linn. (TG) plant belonging to family Verbenaceae is medicinally reported and claims to cure various diseases in Indian traditional system of medicine (Ayurveda) and also in folklore. The purpose of this present study is to examine the hypoglycemic potential of methanol fractions (50, 100 and 200mg/kg body weight) of Tectona grandis bark (MFTG) from defatted hydro-alcoholic extract in normoglycemic, streptozotocin induced (45mg.kg‒1) diabetic and glucose loaded hyperglycemic rats by single and multiple oral administration in comparison to standard drug Glibenclamide (2.5 mg/kg body weight). Initially acute oral toxicity study of MFTG was carried out in rats to estimate the dose for animal study. The study report showed that the MFTG (200mg/kg) significantly (p<0.05 to p<0.01) reduces blood glucose level both in normoglycemic and diabetic rats induced by Streptozotocin and oral glucose loaded methods till the end of 8 hour and 3hour respectively during the single dose study and from the 15th day to 30th day in multi dose study. Hence the present study reveals that MFTG possess significant hypoglycemic activity which inspires the traditional use of the plant for the treatment of diabetes mellitus.

Prenatal Oral (Gavage) Developmental Toxicity Study of Decabromodiphenyl Oxide in Rats

2002 ◽  
Vol 21 (2) ◽  
pp. 83-91 ◽  
Author(s):  
M. L. Hardy ◽  
R. Schroeder ◽  
J. Biesemeier ◽  
O. Manor
Keyword(s):  
Body Weight ◽  
Flame Retardant ◽  
Corn Oil ◽  
Body Weight Gain ◽  
Developmental Toxicity ◽  
Clinical Signs ◽  
Toxicity Study ◽  
Wide Range ◽  
Effect Level ◽  
Effect Of Treatment

Decabromodiphenyl oxide (DBDPO) is a highly effective flame retardant that is primarily used in electrical and electronic equipment with a secondary, but important, application in upholstery textiles. DBDPO, the second largest volume brominated flame retardant in use today, has undergone a wide range of toxicology tests in mammalian species with the results indicating a no-adverse-effect level of ∼1000 mg/kg/day in oral repeated-dose studies. An oral prenatal developmental toxicity study of the commercial DBDPO product (97% purity) was performed under current EPA OPPTS and OECD guidelines. Female Sprague-Dawley rats (25 mated females/group) received 0, 100, 300 or 1000 mg DBPDO/kg/day via gavage in corn oil during gestation days 0 through 19. All females survived until scheduled sacrifice. No clinical signs of toxicity were observed. Pregnancy rates in the control and treated groups ranged from 96% to 100% and provided 23 or more litters in each group for evaluation on gestation day 20. No effect of treatment was seen in maternal gestational parameters (body weight, body weight gain, and food consumption), uterine implantation data, liver weight, or necropsy findings. Likewise, no effect of treatment was seen in fetal body weights, fetal sex distribution, or during the fetal external, visceral, or skeletal examinations. The NOEL (noobservable-effect level) for maternal and developmental toxicity was 1000 mg DBPDO/kg/day, the highest dose level administered on gestation days 0 to 19.

scholarly journals Impaired Insulin Secretion in the Turner Metabolic Syndrome

2004 ◽  
Vol 89 (7) ◽  
pp. 3516-3520 ◽  
Author(s):  
Vladimir K. Bakalov ◽  
Margaret M. Cooley ◽  
Michael J. Quon ◽  
Mei Lin Luo ◽  
Jack A. Yanovski ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Body Mass Index ◽  
Insulin Secretion ◽  
Insulin Sensitivity ◽  
Body Mass ◽  
Cell Function ◽  
Insulin Response ◽  
Area Under The Curve ◽  
Oral Glucose ◽  
Glucose Challenge

Abstract An increased prevalence of impaired glucose homeostasis (IGH) and diabetes mellitus is reported in monosomy X, or Turner syndrome (TS). To determine whether IGH is an intrinsic feature of this syndrome, independent of obesity or hypogonadism, we compared results of a standard oral glucose challenge in age- and body mass index-matched women with TS and with karyotypically normal premature ovarian failure (POF). Fasting glucose levels were normal in both groups, but glucose values after oral glucose challenge were higher in TS [2-h glucose, 135 ± 36 mg/dl (7.5 ± 2.0 mmol/liter) in TS and 97 ± 18 mg/dl (5.4 ± 1.0 mmol/liter) in POF; P &lt; 0.0001]. Glucose-stimulated insulin secretion was lower in TS; e.g. the initial insulin response (ΔI/ΔG30) was decreased by 60% compared with POF (P &lt; 0.0001). We also compared responses to a standard iv glucose tolerance test in women with TS and in age- and body mass index-matched normal women and found that the insulin area under the curve was 50% lower in women with TS (P = 0.003). Insulin sensitivity measured by the quantitative insulin sensitivity check index was higher in women with TS compared with both control groups. Thus, IGH is not secondary to obesity or hypogonadism in TS, but it is a distinct entity characterized by decreased insulin secretion, suggesting that haploinsufficiency for X-chromosome gene(s) impairs β-cell function and predisposes to diabetes mellitus in TS.

Abstract 198: Oral Administration of the Mas Agonist A-1317 Produces Beneficial Cardiometabolic Effects in Rats

Hypertension ◽  
2013 ◽  
Vol 62 (suppl_1) ◽  
Author(s):  
Suellen F Vilas Boas ◽  
Janaina F Braga ◽  
Analina R Silva ◽  
Mariana F Oliveira ◽  
Robson A S Santos
Keyword(s):  
Body Weight ◽  
Glucose Tolerance ◽  
Inclusion Compound ◽  
Metabolic Diseases ◽  
Spontaneously Hypertensive Rat ◽  
Body Weight Gain ◽  
The Body ◽  
Oral Glucose ◽  
Sprague Dawley ◽  
Tissue Mass

The beneficial effects of the Mas/Ang-(1-7) pathway prompted us to develop novel Ang-(1-7) analogues and ligands for Mas. In the present study, we evaluated the cardiometabolic effects of a pharmacological formulation developed by including the Mas agonist A-1317 in hydroxypropyl β-cyclodextrin (HPβCD). The inclusion compound was given orally (10 μg/Kg body weight) to Spontaneously hypertensive rat (SHR) and fructose-fed rats. Mean arterial pressure (MAP) and heart rate (HR) were monitored for 5 hours after administration of a single dose of A-1317-HPβCD in conscious SHR. Seven-weeks-old male Sprague-Dawley rats were fed with either normal rat chow (CTL) or the same diet plus 10% fructose in the drinking water (FFR). For the last 4 wk of a 9-wk period of each diet, a subgroup of each group of animals was treated daily with the oral A-1317 (CTL-A or FFR-A) or with vehicle (CTL-V or FFR-V). Rats were subjected to oral glucose tolerance test (2 g/Kg body weight) concomitantly with the evaluation of plasma insulin levels. A-1317 reduced MAP with the maximum change occurring after 4 hours of administration (Δ=-23±2mmHg). There was no significant effect of A-1317 on HR of SHR. Once a day administration of A-1317 ameliorated all metabolic conditions altered by fructose-feed, including the glucose tolerance with less release of insulin and the decreased in the basal insulinemia. However no change in glycemia was observed. Regarding the lipidic metabolism, there was a decrease in the hepatic and serum tryacilglicerol levels (CTL-V=51±3; CTL-A=44±4; FFR-V=74±6; FFR-A=45±5 mg/dl serum levels), the body weight gain and the epididymal and mesenteric adipose tissue mass. Moreover hepatic and serum cholesterol levels were surprisingly diminished in both treated groups. These data suggest that A-1317 inclusion compound is an innovative therapeutic tool for treatment the cardiovascular and metabolic diseases.

Skeletal muscle glucose metabolism in obesity-prone and obesity-resistant rats

1993 ◽  
Vol 264 (6) ◽  
pp. R1224-R1228 ◽  
Author(s):  
M. J. Pagliassotti ◽  
K. A. Shahrokhi ◽  
J. O. Hill
Keyword(s):  
Skeletal Muscle ◽  
Body Weight ◽  
Weight Gain ◽  
Glucose Metabolism ◽  
Glucose Uptake ◽  
Glycogen Synthase ◽  
Body Weight Gain ◽  
Glycogen Synthesis ◽  
Insulin Resistant ◽  
Wide Range

Ad libitum access to a high-fat (HF) diet produces a wide range of weight gain in rats. Rats most susceptible to weight gain on such a diet (obesity prone; OP) are more insulin resistant after 4-5 wk of diet exposure than are those most resistant (obesity resistant; OR) to weight gain. To investigate whether skeletal muscle glucose metabolism contributes to insulin resistance in this model, insulin-stimulated glucose metabolism was assessed in the perfused hindquarter of rats exposed to either a low-fat (LF, n = 6) or HF diet for 5 wk. Delineation of OP (n = 6) and OR (n = 6) rats was based on body weight gain. OP rats gained 60% more body weight while eating only 10% more energy than OR rats. Single-pass perfusions were carried out for 2 h in the presence of glucose, insulin, and [U-14C]glucose. Insulin-stimulated glucose uptake (mumol.100 g-1.min-1) was 14.2 +/- 0.9 in LF, 11.1 +/- 0.8 in OR, and 6.2 +/- 0.6 in OP. Glucose oxidation (mumol.100 g-1.min-1) was 1.7 +/- 0.3 and 1.2 +/- 0.3 in LF and OR, respectively, but was 0.2 +/- 0.1 in OP. Net glycogen synthesis was significantly reduced in OP compared with OR and LF despite similar glycogen synthase I activity. Muscle triglyceride concentration was not significantly different in OR and OP rats. These results demonstrate significant defects in skeletal muscle glucose uptake and disposal in rats most susceptible to HF diet-induced obesity. Clearly, the heterogeneous response to a HF diet involves not only body weight gain but also skeletal muscle fuel metabolism.

scholarly journals Hypoglycemic Activity through a Novel Combination of Fruiting Body and Mycelia ofCordyceps militarisin High-Fat Diet-Induced Type 2 Diabetes Mellitus Mice

2015 ◽  
Vol 2015 ◽  
pp. 1-10 ◽  
Author(s):  
Sung-Hsun Yu ◽  
Szu-Yu Tina Chen ◽  
Wei-Shan Li ◽  
Navneet Kumar Dubey ◽  
Wei-Hong Chen ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Body Weight ◽  
Adipose Tissue ◽  
Blood Glucose ◽  
Fruiting Body ◽  
High Fat Diet ◽  
Oral Glucose ◽  
High Fat ◽  
Type 2 Dm

Diabetes mellitus (DM) is currently ranked among leading causes of death worldwide in which type 2 DM is reaching an epidemic proportion. Hypoglycemic medications for type 2 DM have either proven inadequate or posed adverse effects; therefore, the Chinese herbal products are under investigation as an alternative treatment. In this study, a novel combination of fruiting body and mycelia powder of herbalCordyceps militarisnumber 1 (CmNo1) was administered to evaluate their potential hypoglycemic effects in high-fat diet- (HFD-) induced type 2 DM in C57BL/6J mice. Body weight, fasting blood glucose (FBG), oral glucose tolerance test (OGTT), and blood biochemistry indexes were measured. Results indicated that CmNo1 lowered the blood glucose level by increasing insulin sensitivity, while no change in body weight was observed. Increased protein expression of IRS-1, pIRS-1, AKT, pAKT, and GLUT-4 in skeletal muscle and adipose tissue was found indicating restoration of insulin signaling. Additionally, PPAR-γexpression in adipose tissue restored the triglyceride and cholesterol levels. Finally, our results suggest that CmNo1 possesses strong hypoglycemic, anticholesterolemic, and antihypertriglyceridemic actions and is more economical alternate for DM treatment.

scholarly journals Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control?

2008 ◽  
Vol 158 (6) ◽  
pp. 773-784 ◽  
Author(s):  
Luc F Van Gaal ◽  
Stephen W Gutkin ◽  
Michael A Nauck
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Body Weight ◽  
Cell Function ◽  
Β Cell ◽  
Β Cell Function ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

Type 2 diabetes mellitus is associated with progressive decreases in pancreatic β-cell function. Most patients thus require increasingly intensive treatment, including oral combination therapies followed by insulin. Fear of hypoglycemia is a potential barrier to treatment adherence and glycemic control, while weight gain can exacerbate hyperglycemia or insulin resistance. Administration of insulin can roughly mimic physiologic insulin secretion but does not address underlying pathophysiology. Glucagon-like peptide 1 (GLP-1) is an incretin hormone released by the gut in response to meal intake that helps to maintain glucose homeostasis through coordinated effects on islet α- and β-cells, inhibiting glucagon output, and stimulating insulin secretion in a glucose-dependent manner. Biological effects of GLP-1 include slowing gastric emptying and decreasing appetite. Incretin mimetics (GLP-1 receptor agonists with more suitable pharmacokinetic properties versus GLP-1) significantly lower hemoglobin A1c, body weight, and postprandial glucose excursions in humans and significantly improve β-cell function in vivo (animal data). These novel incretin-based therapies offer the potential to reduce body weight or prevent weight gain, although the durability of these effects and their potential long-term benefits need to be studied further. This article reviews recent clinical trials comparing therapy with the incretin mimetic exenatide to insulin in patients with oral treatment failure, identifies factors consistent with the use of each treatment, and delineates areas for future research.

Basal metabolic rate in lambs and young sheep

1974 ◽  
Vol 25 (6) ◽  
pp. 957 ◽  
Author(s):  
NMcC Graham ◽  
TW Searle ◽  
DA Griffiths
Keyword(s):  
Growth Rate ◽  
Body Weight ◽  
Metabolic Rate ◽  
Basal Metabolic Rate ◽  
Body Weight Gain ◽  
Adult Cattle ◽  
Adult Sheep ◽  
Free Weight ◽  
Wide Range ◽  
Average Adult

Basal metabolic rate (BMR) was determined in 56 crossbred sheep, up to 10 observations being made on each animal between 1 week of age and 2¼ years. The level of feeding was varied amongst the sheep so that there was a wide range in growth rate at each age. BMR was estimated as heat production under standard conditions of fasting. Trends during fasting were studied in four sheep at ages 3 weeks, 2 months and 9 months. The effects on BMR of body weight (or fat-free weight), age, prior growth rate and prior nutrition were examined statistically by estimating the parameters of a series of model equations by a least squares iterative method. Analysis of lamb and sheep data separately and combined showed that all these variates contributed significantly to BMR. Of the variance of BMR, 89% was accounted for in a body weight term, kgx, in which the value of x was not significantly different from ¾ if one or more of the other variates were in the model; x was unity when fat-free weight was used instead of body weight. If body weight was used alone, x was smaller for both lambs and weaners, being c. 0.60; with fat-free weight the values for lambs and weaners were 0.71 and 0.96 respectively. Age, growth rate and level of feeding were of approximately equal importance, together accounting for a further 6% of the total variance. BMR declined by c. 8% per annum and was affected to the extent of 2.8 kJ per gram body weight gain and 46 kJ per MJ digestible energy intake before fasting (all values per 24 hr). Thus an increase in growth rate in a lamb from zero to maximal (0.3 kg/day) caused BMR to increase by 50%, and an increase of food intake by 1 kg/day in an average adult sheep caused BMR to increase by 10%. For any given set of these variates, BMR was 23% higher in milk-fed lambs than in weaned sheep. An equation was derived for sheep in general; the residual standard deviation was c. 300 kJ/24 hr, or 7-8% of BMR in an average adult sheep. Some evidence was cited to show that this equation may be used to predict BMR in growing and adult cattle by multiplying the whole expression by 1.3.

scholarly journals Carbohydrate-Responsive Gene Expression in the Adipose Tissue of Rats

Endocrinology ◽  
2010 ◽  
Vol 151 (1) ◽  
pp. 153-164 ◽  
Author(s):  
Kartik Shankar ◽  
Amanda Harrell ◽  
Ping Kang ◽  
Rohit Singhal ◽  
Martin J. J. Ronis ◽  
...  
Keyword(s):  
Gene Expression ◽  
Body Composition ◽  
Body Weight ◽  
Adipose Tissue ◽  
Body Weight Gain ◽  
Caloric Intake ◽  
Oral Glucose ◽  
Sprague Dawley ◽  
Simple Carbohydrates ◽  
The Impact

Abstract Although obesity is often associated with high-fat diets, it can develop from a variety of meal patterns. Excessive intake of simple carbohydrates is one consistent eating behavior leading to obesity. However, the impact of overconsumption of diets with high carbohydrate to fat ratios (C/F) on body composition and global adipose tissue gene expression remains unclear. We used total enteral nutrition to evaluate the effects of caloric intake and C/F on body weight gain and development of obesity. Female Sprague Dawley rats were fed diets with either low C/F or high C/F (HC) (reflecting a 19.5-fold increase in C/F) at two levels of caloric intake: 187 or 220 kcal/kg3/4 · d (15% excess) for 4 wk. At the end of the study period, rats fed HC diets had about 20% higher body weight at either caloric intake compared with rats fed low C/F diets (P &lt; 0.05). Body composition (assessed by nuclear magnetic resonance, computerized tomography, and adipose tissue weights) revealed higher percent fat mass (P &lt; 0.05) in HC rats. Obesity was associated with increased serum resistin, leptin, fasting hyperinsulinemia, and insulin resistance after an oral glucose challenge (P &lt; 0.05). Microarray analyses of adipose tissues revealed HC diets led to changes in 270 and 464 transcripts at 187 and 220 kcal/kg3/4 · d intakes. Genes regulating glucose transport, glycolysis, fatty acid and triglyceride biosynthesis, desaturation and elongation, adipogenesis, and adipokines were affected by HC diets. These results suggest that C/F and interactions with excessive caloric intake per se may regulate body composition and play important roles in the development of obesity and metabolic syndrome.

Sign in / Sign up

Export Citation Format

Share Document